0001209191-23-016074.txt : 20230303
0001209191-23-016074.hdr.sgml : 20230303
20230303203720
ACCESSION NUMBER: 0001209191-23-016074
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230301
FILED AS OF DATE: 20230303
DATE AS OF CHANGE: 20230303
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Walker Neal
CENTRAL INDEX KEY: 0001604457
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37581
FILM NUMBER: 23707239
MAIL ADDRESS:
STREET 1: 15 NEW ENGLAND EXECUTIVE PARK
CITY: BURLINGTON
STATE: MA
ZIP: 01803
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc.
CENTRAL INDEX KEY: 0001557746
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 460571712
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 640 LEE ROAD
STREET 2: SUITE 200
CITY: WAYNE
STATE: PA
ZIP: 19087
BUSINESS PHONE: 484-324-7933
MAIL ADDRESS:
STREET 1: 640 LEE ROAD
STREET 2: SUITE 200
CITY: WAYNE
STATE: PA
ZIP: 19087
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-03-01
0
0001557746
Aclaris Therapeutics, Inc.
ACRS
0001604457
Walker Neal
C/O ACLARIS THERAPEUTICS, INC.
640 LEE ROAD, SUITE 200
WAYNE
PA
19087
1
0
0
0
Common Stock
2023-03-01
4
M
0
96150
A
1271913
D
Common Stock
2023-03-01
4
M
0
18275
A
1290188
D
Common Stock
2023-03-01
4
M
0
24000
A
1314188
D
Common Stock
2023-03-02
4
S
0
29000
12.3651
D
1285188
D
Common Stock
2023-03-02
4
M
0
18254
A
1303442
D
Common Stock
2023-03-03
4
S
0
30240
12.6346
D
1273202
D
Restricted Stock Units
2023-03-01
4
M
0
96150
0.00
D
Common Stock
96150
0
D
Restricted Stock Units
2023-03-01
4
M
0
18275
0.00
D
Common Stock
18275
36550
D
Restricted Stock Units
2023-03-01
4
M
0
24000
0.00
D
Common Stock
24000
72000
D
Restricted Stock Units
2023-03-02
4
M
0
18254
0.00
D
Common Stock
18254
18254
D
Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 pursuant to preexisting sell-to-cover elections.
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.88 to $12.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 and March 2, 2023 pursuant to preexisting sell-to-cover elections.
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.39 to $12.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023.
The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023.
The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023.
The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023.
/s/ Mark Ballantyne, Attorney-in-fact
2023-03-03